Cargando…

Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats

BACKGROUND: Opioid use disorders are serious contributors to the harms associated with the drug use. Unfortunately, therapeutic interventions for opioid addicts after detoxification have been limited and not sufficiently effective. Recently, several studies have led to promising results with disulfi...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankowska, Małgorzata, Surówka, Paulina, Suder, Agata, Pieniążek, Renata, Pukło, Renata, Jastrzębska, Joanna, Daniel, Władysława A., Filip, Małgorzata, Zadrożny-Bujalska, Magdalena, Kleczkowska, Patrycja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599263/
https://www.ncbi.nlm.nih.gov/pubmed/34236605
http://dx.doi.org/10.1007/s43440-021-00307-2
_version_ 1784600910907834368
author Frankowska, Małgorzata
Surówka, Paulina
Suder, Agata
Pieniążek, Renata
Pukło, Renata
Jastrzębska, Joanna
Daniel, Władysława A.
Filip, Małgorzata
Zadrożny-Bujalska, Magdalena
Kleczkowska, Patrycja
author_facet Frankowska, Małgorzata
Surówka, Paulina
Suder, Agata
Pieniążek, Renata
Pukło, Renata
Jastrzębska, Joanna
Daniel, Władysława A.
Filip, Małgorzata
Zadrożny-Bujalska, Magdalena
Kleczkowska, Patrycja
author_sort Frankowska, Małgorzata
collection PubMed
description BACKGROUND: Opioid use disorders are serious contributors to the harms associated with the drug use. Unfortunately, therapeutic interventions for opioid addicts after detoxification have been limited and not sufficiently effective. Recently, several studies have led to promising results with disulfiram (DSF), a dopamine β-hydroxylase (DBH) inhibitor, showing that it is a potent agent against not only alcohol but also addiction to various drugs. MATERIALS AND METHODS: This study was designed to examine whether DSF and nepicastat (NEP; another DBH inhibitor) modify morphine intake and reinstatement of seeking-behavior using the rat model of intravenous morphine self-administration. Additionally, we intended to estimate the effects of both inhibitors on the locomotor activity as well as on extracellular dopamine and its metabolite levels in the nucleus accumbens using microdialysis in naive rats. RESULTS: We demonstrated that both DBH inhibitors reduced responding to morphine self-administration. Moreover, DSF and NEP administered acutely before reinstatement test sessions consistently attenuated the reinforcing effects of morphine and a morphine-associated conditioned cue. The observed effects for lower doses (6.25–25 mg/kg; ip) of both DBH inhibitors seem to be independent of locomotor activity reduction and dopamine level in the nucleus accumbens. Neither DSF nor NEP administered daily during morphine abstinence with extinction training sessions had any effect on active lever-responding and changed the reinstatement induced by morphine priming doses. Reinstatement of drug-seeking behavior induced by a conditioned cue previously associated with morphine delivery was attenuated following repeated administration of DSF or NEP during the abstinence period. CONCLUSION: These results seem to point to the significance  of DBH inhibition as a potential pharmacotherapy against morphine use disorders. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8599263
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85992632021-11-24 Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats Frankowska, Małgorzata Surówka, Paulina Suder, Agata Pieniążek, Renata Pukło, Renata Jastrzębska, Joanna Daniel, Władysława A. Filip, Małgorzata Zadrożny-Bujalska, Magdalena Kleczkowska, Patrycja Pharmacol Rep Article BACKGROUND: Opioid use disorders are serious contributors to the harms associated with the drug use. Unfortunately, therapeutic interventions for opioid addicts after detoxification have been limited and not sufficiently effective. Recently, several studies have led to promising results with disulfiram (DSF), a dopamine β-hydroxylase (DBH) inhibitor, showing that it is a potent agent against not only alcohol but also addiction to various drugs. MATERIALS AND METHODS: This study was designed to examine whether DSF and nepicastat (NEP; another DBH inhibitor) modify morphine intake and reinstatement of seeking-behavior using the rat model of intravenous morphine self-administration. Additionally, we intended to estimate the effects of both inhibitors on the locomotor activity as well as on extracellular dopamine and its metabolite levels in the nucleus accumbens using microdialysis in naive rats. RESULTS: We demonstrated that both DBH inhibitors reduced responding to morphine self-administration. Moreover, DSF and NEP administered acutely before reinstatement test sessions consistently attenuated the reinforcing effects of morphine and a morphine-associated conditioned cue. The observed effects for lower doses (6.25–25 mg/kg; ip) of both DBH inhibitors seem to be independent of locomotor activity reduction and dopamine level in the nucleus accumbens. Neither DSF nor NEP administered daily during morphine abstinence with extinction training sessions had any effect on active lever-responding and changed the reinstatement induced by morphine priming doses. Reinstatement of drug-seeking behavior induced by a conditioned cue previously associated with morphine delivery was attenuated following repeated administration of DSF or NEP during the abstinence period. CONCLUSION: These results seem to point to the significance  of DBH inhibition as a potential pharmacotherapy against morphine use disorders. GRAPHIC ABSTRACT: [Image: see text] Springer International Publishing 2021-07-08 2021 /pmc/articles/PMC8599263/ /pubmed/34236605 http://dx.doi.org/10.1007/s43440-021-00307-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Frankowska, Małgorzata
Surówka, Paulina
Suder, Agata
Pieniążek, Renata
Pukło, Renata
Jastrzębska, Joanna
Daniel, Władysława A.
Filip, Małgorzata
Zadrożny-Bujalska, Magdalena
Kleczkowska, Patrycja
Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
title Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
title_full Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
title_fullStr Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
title_full_unstemmed Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
title_short Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
title_sort treatment with dopamine β-hydroxylase (dbh) inhibitors prevents morphine use and relapse-like behavior in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599263/
https://www.ncbi.nlm.nih.gov/pubmed/34236605
http://dx.doi.org/10.1007/s43440-021-00307-2
work_keys_str_mv AT frankowskamałgorzata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT surowkapaulina treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT suderagata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT pieniazekrenata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT pukłorenata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT jastrzebskajoanna treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT danielwładysławaa treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT filipmałgorzata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT zadroznybujalskamagdalena treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats
AT kleczkowskapatrycja treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats